Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute and Associate Editor for Breast Cancer at ESMO Open, shared a post on LinkedIn:
“ADCs: guided missiles, slow chemo infusion, or something else?
In our latest free-access commentary, led by Matthew Vogel and just out in JCO, we review the latest evidence on ADCs’ mechanism of action, diving deep into their fascinating complexity.”
Title: Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates
Authors: Matthew Vogel, Raffaele Colombo, Paolo Tarantino
Read the Full Article.
